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Abstract 
Background and purposes: Anticoagulant therapy is recommended for the secondary 
prevention of stroke in patients with atrial fibrillation (AF). The identification of patients 
at high risk for early recurrence, which are potential candidates to prompt 
anticoagulation, is crucial to justify the risk of bleeding associated with early 
anticoagulant treatment. The aim of this study was to evaluate in patients with acute 
ischemic stroke and AF the association between findings at trans-thoracic 
echocardiography (TTE) and 90 day recurrence.    
Methods: In consecutive patients with acute ischemic stroke and AF, TTE was performed 
within 7 days from hospital admission. Study outcomes were recurrent ischemic 
cerebrovascular events (stroke or TIA) and systemic embolism. 
Results: 854 patients (mean age 76.3±9.5 years) underwent a TTE evaluation; 63 
patients (7.4%) had at least a study outcome event. Left atrial thrombosis was present in 
11 patients (1.3%) among whom 1 had recurrent ischemic event. Left atrial enlargement 
was present in 548 patients (64.2%) among whom 51 (9.3%) had recurrent ischemic 
events. The recurrence rate in the 197 patients with severe left atrial enlargement was 
11.7%. On multivariate analysis, the presence of atrial enlargement (OR=2.13; 95% CI 
1.06-4.29, p=0.033) and CHA2DS2-VASc score (OR 1.22; 95% CI 1.04-1.45, p=0.018, for 
each point increase) were correlated with ischemic recurrences.  
Conclusion: In patients with AF-associated acute stroke, left atrial enlargement is an 
independent marker of recurrent stroke and systemic embolism. The risk of recurrence is 
accounted for by severe atrial enlargement. TTE-detected left atrial thrombosis is 
relatively uncommon.  
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Background 
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an 
elevated risk of ischemic stroke and systemic thromboembolism. After an acute stroke, 
patients with AF have a high risk of early recurrence that is about 8% within 90 days 
from the acute event (1).  
Anticoagulant therapy is effective for the secondary prevention of stroke in patients with 
AF. The balance between the risk of recurrence and bleeding associated to anticoagulant 
therapy for any given patient remains unclear. The identification of patients at high risk 
for early recurrence, which are potential candidates to prompt anticoagulation, is crucial 
to justify the risk of bleeding associated with early anticoagulant treatment. 
Echocardiography, transthoracic (TTE) or less commonly transesophageal (TEE), is 
included in the work-up of patients with AF and stroke. In these patients, 
echocardiography detected left atrial thrombosis supports early anticoagulation (2). 
Likewise, in patients with acute stroke, left atrial enlargement, has been associated with 
the risk of stroke recurrence (3). 
The aim of this study was to evaluate the potential association between TTE findings in 
the early stage of cerebral ischemia (within 7 days from hospital admission) and the risk 
of 90-day thromboembolic recurrence in patients with acute ischemic stroke and AF. 
 
Methods 
Patients 
Data for this analysis were extracted from the database of a prospective multicentre 
study which enrolled consecutive patients with acute stroke and AF (the RAF study) (1). 
This study, carried out between January 2012 and March 2014, enrolled 1,029 
consecutive patients in 29 Stroke Units from Europe and Asia.  
On admission, the severity of acute stroke was assessed using the National Institutes of 
Health Stroke Scale (NIHSS); all investigators were certified about the use of this scale.  
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AF was classified as paroxysmal (episodes terminating spontaneously within 7 days), 
persistent (episodes lasting more than 7 days requiring pharmacologic and/or electrical 
stimulation), or permanent (persisting for more than 1 year, either because cardioversion 
failed or was not attempted).  
 
Risk factors 
Data on known stroke risk factors were collected as reported in the main paper (1). 
A cerebral computed tomography (CT) or magnetic resonance (MR) was performed on 
admission in all patients to exclude intracranial hemorrhage. A second cerebral CT scan 
or MR was performed 48-72 h from stroke onset. The sites and sizes of the qualifying 
infarcts were determined based on standard templates (4,5) as follows: (a) small, when a 
lesion was ≤1.5 cm in the anterior or posterior circulation, (b) medium, when a lesion 
was in a cortical superficial branch of middle cerebral artery [MCA], in the MCA deep 
branch, in the internal border zone territories, in a cortical superficial branch of posterior 
cerebral artery [PCA], in the PCA branch or in a cortical superficial branch of the anterior 
cerebral artery [ACA]), (c) large anterior, when a lesion involved the complete territory of 
MCA, PCA, or ACA, in 2 cortical superficial branches of MCA, in a cortical superficial 
branch of MCA associated to the MCA deep branch, or in more than 1 artery territory [eg, 
MCA associated to ACA territories]), (d) large posterior, when a lesion was ≥1.5 cm in the 
brain stem or cerebellum (6). 
 
Echocardiogram evaluation 
TTE was performed within 7 days form stroke onset by a local cardiologist using a 
standardized protocol. Patients were imaged in the left lateral decubitus. Images were 
obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal (standard 
long- and short-axis images) and apical views (standard long-axis, 2- and 4-chamber 
images). Standard 2-dimensional and color Doppler data, triggered to the QRS complex, 
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were saved in cine loop format. Pulsed and continuous wave Doppler data were also 
stored digitally.  
TTE analysis included the presence of: 1) intra-cardiac thrombus; 2) left atrial 
enlargement; 3) mitral valve stenosis or regurgitation; 4) aortic valve stenosis or 
regurgitation; 5) tricuspidal valve stenosis or regurgitation; 6) dilated cardiomyopathy 
with left ventricular ejection ≤40%. Presence of pacemaker, biological or mechanical valve 
(mitral or aortic) was also assessed.  
The presence of an intra-cardiac thrombus was diagnosed by the presence of an echo-
dense mass distinct from the endocardium in any cardiac cavity (7).  
Left atrial enlargement was defined following the American Society of Echocardiography 
guidelines measuring the left atrial diameter or volume taking into account the difference 
between sexes (8). The severity of atrial enlargement was defined according the 
definitions described in table 1. 
Mitral, aortic and tricuspid stenoses or regurgitations were dichotomized as absent or 
present (mild/moderate/severe) following the definitions of published guidelines (9,10).  
 
Evaluation of outcome 
Patients were followed-up prospectively by office or telephone interviews. Study outcome 
was the composite of recurrent ischemic cerebrovascular events (stroke or TIA) and 
symptomatic systemic embolisms. Recurrent ischemic stroke was defined as the sudden 
onset of a new focal neurological deficit of vascular origin in a site consistent with the 
territory of a major cerebral artery and after exclusion of cerebral hemorrhage at 
neuroimaging. TIA was defined as a transient episode of neurological dysfunction caused 
by focal brain ischemia without acute infarction. Systemic embolism was defined as an 
acute vascular occlusion of an extremity or organ confirmed by imaging, surgery, or 
autopsy. The diagnosis of systemic embolism was independently adjudicated by vascular 
surgeons.  
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Statistical analysis 
Differences in the characteristics of patients with or without outcome events were tested 
using χ-square test. Correlations between TTE characteristics and risk of recurrent 
ischemic events were sought by multiple logistic regression analysis. The variables 
included in the model other than the TTE characteristics were the type of AF, CHA2DS2-
VASc score, cardiovascular risk factors, reperfusion therapy, the severity of stroke on 
admission according to NIHSS score, the presence of pacemaker, biological or 
mechanical valve, anti-thrombotic treatment and size of the lesion. 
The relationship between the recurrent ischemic events and the TTE characteristics, 
correlated to outcome on multivariate analysis, were also explored with Cox proportional 
hazard models. The Cox model provides an estimate of the effect of TTE characteristics 
on recurrent ischemic events after adjusting for: lesion sizes, age, sex, type of AF, NIHSS 
on admission, anticoagulant treatment, the presence of pacemaker and the histories of 
hypertension, diabetes, previous stroke/TIA and congestive heart failure. 
 
Results 
Overall, 1,037 consecutive patients were included in the study. Of these, 8 patients were 
excluded for incomplete data while 1,029 patients were included in the analysis; of these, 
854 patients had a TTE evaluation. The 175 patients did not undergo TTE evaluation for 
the following reasons: 34 (19.4%) early death, 86 (49.2%) severe stroke and 55 (31.4%) 
for unknown reasons. The characteristics of the patients with and without TTE 
evaluation are summarized in table 2. Patients without TTE evaluation were older, with a 
more severe stroke and with more cardiovascular risk factors. 
Mitral valve disease was present in 360 patients (42.2%; 275 regurgitations and 85 
stenosis) while aortic valve disease was present in 230 patients (24.9%; regurgitation in 
47 and stenosis in 183). In 168 patients (19.7%), mitral valve disease was associated 
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with aortic valve disease. Intra-cardiac thrombosis, all in left atrium, was present in 11 
patients (1.3%) while atrial enlargement was present in 548 patients (64.2%). Atrial 
enlargement as mild in 145 patients (16.9%), moderate in 203 patients (23.8%) and 
severe in 197 (23.1%). 
Within 90 days, 63 patients (7.4%) of those who underwent TTE had at least a study 
outcome event: 49 recurrent ischemic stroke, 8 TIA and 6 symptomatic systemic 
embolism. Three patients had two study outcome events. The TTE characteristics of the 
patients with and without outcome event are summarized in table 3. Atrial enlargement 
was present in 81% of the patients with recurrent ischemic events. The risk of outcome 
event increased with the severity of atrial enlargement (p for trend: 0.012) (Fig.1). The 
recurrence rate in the 197 patients with severe left atrial enlargement was 11.7%.  
Therapy with anticoagulants after the index stroke event was performed in 80.5% of the 
patients without atrial enlargement, in 79.3% with mild atrial enlargement, in 77.6% 
with moderate atrial enlargement and in 77.1% of the patients with severe atrial 
enlargement (p for trend: 0.78). 
On multivariate analysis, the presence of atrial enlargement (OR=2.13; 95% CI 1.06-
4.29, p=0.033) and CHA2DS2-VASc score (OR 1.22; 95% CI 1.04-1.45, p=0.018, for each 
point increase) were correlated with ischemic recurrent event. Small ischemic lesion was 
inversely correlated with ischemic recurrent event (OR 0.55; 95% CI 0.30-1.00, p=0.05). 
The presence of pacemaker showed an OR 2.10; 95% CI 0.97-4.60, p=0.06. When in the 
model the variable atrial enlargement was introduced as mild, moderate or severe, only 
the presence of severe atrial enlargement was correlated with an outcome event (OR: 
2.05; 95% CI 1.08-2.87, p=0.027). All the remaining TTE characteristics were not 
correlated with outcome event. 
Figure 2 shows the adjusted analysis using the Cox regression model that evidences the 
different risk for an ischemic outcome event according to the severity of atrial 
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enlargement within 90 days. This analysis, was adjusted for age, sex, CHA2DS2-VASc 
score, lesion size, anticoagulant therapy and NIHSS score on admission. 
 
Discussion  
In this prospective study in patients with acute stroke and AF, TTE showed a left atrial 
thrombus in about 1% and an atrial enlargement in 65% of the patients. The presence of 
atrial enlargement was associated with a higher risk of an ischemic recurrence within 90 
days. This association was accounted for by severe atrial enlargement.  
In clinical practice, for the fear of an early recurrence, TTE is usually performed in acute 
phase of stroke to detect a thrombus and to start anticoagulant therapy earlier. This 
study showed the futility of acute TTE for detection of intra-cardiac thrombosis. About 
17% of the patients did not undergo TTE in the acute phase of stroke and these patients 
were older and with more severe neurological deficit. Therefore, it is possible that in 
these patients, the rate of intra-cardiac thrombus was higher. However, these are not the 
typical patients in whom anticoagulation would be started promptly.  
Several studies demonstrated that TEE is superior to TTE for identification of a cardiac 
embolic source in patients with TIA or stroke (11,12). De Brujn et al. (11), in patients 
with acute stroke, found a thrombus in 17% of the patients using TEE compared to 2% 
using TTE. Thus, in patients with acute stroke and AF, TEE is probably more useful to 
detect intra-cardiac thrombosis. However, this examination in patients with acute stroke 
is not easy.  
Our study showed that atrial enlargement, especially severe, was independently 
associated with early stroke recurrence. Several studies found that moderate to severe 
left atrial enlargement is an independent marker of recurrent stroke of embolic subtypes 
in patients with ischemic stroke even in patients without evidence of AF (3,13). 
Furthermore, atrial dilatation is correlated with more severe stroke (14).  
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An association between ischemic recurrent events and the presence of a valve prosthesis, 
biological or mechanical, was not found but the number of patients with valve prosthesis 
was low (17 patients with biological prosthesis and 40 with mechanical prosthesis). 
This study has several limitations and strengths. The evaluation of TTE and the 
adjudication of the outcome events were not centralized. Not all the patients had TTE 
examination and this might have introduced some selection bias.  
Strengths of our study include the prospective and multicentre design with an adequate 
sample size of consecutive patients, making the results robust and generalizable. 
Furthermore, we collected data on a wide range of potentially confounding risk factors, 
allowing us to estimate the independent effects of TTE characteristics evaluated. 
In summary, in patients with AF-associated acute stroke, atrial enlargement is an 
independent marker of recurrent stroke and systemic embolism. Left atrial thrombosis is 
relatively uncommon. Future studies are needed to evaluate whether left atrial 
enlargement could be used to drive prompt anticoagulant therapy in patients with acute 
stroke and AF to reduce the risk of recurrence. 
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Figure legends 
Figure 1. The risk of an ischemic outcome event according to the severity of atrial 
enlargement (p for trend: 0.012). 
Figure 2. The cumulative risk of an ischemic outcome event according to the 
severity of atrial enlargement using Cox regression model. 
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Table1. Definitions of left atrial enlargement according to the severity (Lang et al, 2005) 
 
 Women   
 
 Men    
 Reference 
Range 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
Reference 
Range 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
 
Atrial dimension         
LA diameter, cm 2.7-3.8 3.9-4.2 4.3-4.6 ≥4.7 3.0-4.0 4.1-4.6 4.7-5.2 ≥5.2 
LA 
diameter/BSA,cm/m2 
 
 
1.5-2.3 
 
2.4-2.6 
 
2.7-2.9 
 
≥3.0 
 
1.5-2.3 
 
2.4-2.6 
 
2.7-2.9 
 
≥3.0 
Atrial area         
LA area, cm2 
 
≤20 20-30 30-40 >40 ≤20 20-30 30-40 >40 
Atrial volumes         
LA volume, mL 22-52 53-62 63-72 ≥73 18-58 59-68 69-78 ≥79 
LA 
volume/BSA,mL/m2 
 
22±6 
 
29-33 
 
34-39 
 
≥40 
 
22±6 
 
29-33 
 
34-39 
 
≥40 
LA: left atrial 
BSA: body surface area in m2
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Table 2. Characteristics of the patients with or without TTE evaluation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Transient Ischemic attack 
**Congestive heart failure 
***Myocardial infarction 
****Stroke/TIA/systemic embolism 
 Total 
(n=1029) 
 
With TTE 
(n=854) 
Without TTE 
(n=175)  
p  
Age (mean, years) 77.2 ± 9.5 76.3 ± 9.5  81.4 ± 8.4 0.0001 
NHISS (mean)  9.2 ±7.3 8.9 ± 7.0 10.7 ± 9.0 0.002 
     
Sex male 468 (45.5%) 398 (46.6%) 70 (40.0%) 0.1 
Diabetes mellitus 264 (25.6%) 221 (26.0%) 43 (24.8%) 0.7 
Statins 260 (25.3%) 213 (25.2%) 47 (27.3%) 0.5 
Hipertension 821 (79.8%) 676 (79.8%) 145 (83.8%) 0.2 
Hyperlipidemia 332 (32.3%) 282 (33.4%) 50 (29.2%) 0.3 
History stroke/TIA* 266 (25.8%) 205 (24.3%) 61 (35.5%) 0.04 
Smoking 190 (18.5%) 158 (18.7%) 32 (18.5%) 0.5 
Alcoholism 68 (6.6%) 57 (6.7%) 11 (6.4%) 1.0 
History of CHF** 193 (18.7%) 167 (19.6%) 26 (15.0%) 0.2 
History of MI*** 166 (16.1%) 142 (16.8) 24 (13.9%) 0.4 
     
Paroxysmal AF 364 (35.4%) 316 (37.0%) 48 (27.9%) 0.023 
Permanent AF 473 (46.0%) 385 (45.1%) 88 (51.2%) 0.1 
Persistent AF 191 (18.6%) 155 (18.2%) 36 (20.9%) 0,3 
     
Pacemaker 85 (8.3%) 70 (8.2%) 15 (8.7%) 0.8 
     
rtPA 184 (17.9%) 158 (18.5%) 26 (15.1%) 0.3 
Intra-arterial 
revascularization  
 
46 (4.5%) 
 
43 (5.1%) 
 
3 (1.7%) 
 
0.067 
     
CHA2DS2-VASc 0 17 (1.6%) 16 (1.9%) 1 (0.6%) 0.053 
                        1 54 (5.2%) 51 (6.0%) 3 (1.7%)  
                        2 91 (8.8%) 82 (9.6%) 9 (5.1%)  
                        3 200 (19.4%) 167 (19.5%) 33 (18.9%)  
                        4 243 (23.6%) 203 (23.8%) 40 (22.9%)  
                        5 206 (20.0%) 161 (18.8%) 45 (25.7%)  
                        6 129 (12.5%) 104 (12.2%) 25 (14.3%)  
                        7 66 (6.4%) 51 (6.0%) 15 (8.6%)  
                        8-9 23 (2.2) 19 (2.2%) 4 (2.3%)  
     
Therapy with 
anticoagulants after 
index stroke 
 
766 (74.4%) 
 
673 (78.8%) 
 
93 (53.1%) 
 
0.0001 
     
Recurrent ischemic 
event**** 
77 (7.6%) 63 (7.4%) 14 (8.0%) 0.7 
Disability at 90 days 
(mRS≥3) 
510 (49.5%) 403 (47.6%) 107 (61.8%) 0.001 
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Table 3. TTE characteristics in patients with and without outcome event 
 
 Total 
(n=854) 
Without outcome event 
(n =791) 
With outcome event 
(n= 63) 
 
p 
Atrial enlargement 548 (64.2%) 497 (62.8%) 51 (81.0%) 0.004 
Mild 145 (16.9%) 133 (16.9%) 12 (19.0%) 0.6 
Moderate 203 (23.8%) 187 (23.7%) 16 (25.4) 0.7 
Severe 197 (23.1%) 174 (22.0%) 23 (36.5%) 0.013 
Intracardiac thrombus 11 (1.3%) 10 (1.3%) 1 (1.6%) 0.5 
Cardiomyopathy*  99 (11.6%) 89 (11.3%) 10 (15.9) 0.3 
Mitral disease 360 (42.2%) 323 (40.1%) 37 (58.7%) 0.021 
Aortic disease 230 (26.9%) 205 (25.9%) 25 (39.7%) 0.026 
Tricuspidal disease 213 (24.9%) 189 (23.9%) 24 (38.1%) 0.016 
Biological aortic valve 10 (1.2%) 10 (1.2%) 0 1.0 
Mechanical aortic valve 17 (2.0%) 15 (1.8%) 2 (3.0%) 0.3 
Biological mitral valve 7 (0.8%) 7 (0.8%) 0 1.0 
Mechanical mitral valve 23 (2.7%) 20 (2.4%) 3 (4.5%) 0.2 
*left ventricular ejection ≤40% 
 


